LoginSign Up
Oraya Therapeutics

Oraya Therapeutics

Oraya Therapeutics is a biotechnology company developing non-invasive therapies for eye diseases that is headquartered in San Francisco, California and was founded in 2007 by Michael Gertner.

Oraya Therapeutics is a biotechnology company using non-invasive strategies to treat inflammatory and neovascular diseases of the eye. The company was founded by Michael Gertner in 2007, and is headquartered in San Francisco, California. Oraya Therapeutics is developing a stereotactic radiotherapy system called the IRay for treating wet macular degeneration and choroidal metastases (eye cancer). The IRay system uses x-ray and laser beams to target problematic regions of the optic nerve, delivering approximately a radioactive dose equivalent to 1/10 of a head CT scan.

Funding

Series A

On June 18, 2007 Oraya Therapeutics closed their series A funding round with $4 million in funding from Essex Woodlands Health Ventures.

Series B

On January 11, 2008 Oraya Therapeutics closed their series B funding round with $18 million in funding from Synergy Life Science Partner and Essex Woodlands Health Ventures.

Series C

On July 20, 2009 Oraya Therapeutics closed their series C funding round with $42 million in funding from Scale Venture Partners, Domain Associates, Essex Woodlands Health Ventures, and Synergy Life Science Partner.

Series D

On May 14, 2014 Oraya Therapeutics closed their series D funding round with $25.1 million in funding from undisclosed investors.

Timeline

People

Name
Role
Related Golden topics

Michael Gertner

Founder

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Oraya Therapy Treatment Video-- Full version with treatment animation

October 28, 2015

Companies

Company
CEO
Location
Products/Services

References